ACT ZOLEDRONIC ACID SOLUTION

Страна: Канада

Язык: английский

Источник: Health Canada

Активный ингредиент:

ZOLEDRONIC ACID (ZOLEDRONIC ACID MONOHYDRATE)

Доступна с:

ACTAVIS PHARMA COMPANY

код АТС:

M05BA08

ИНН (Международная Имя):

ZOLEDRONIC ACID

дозировка:

5MG

Фармацевтическая форма:

SOLUTION

состав:

ZOLEDRONIC ACID (ZOLEDRONIC ACID MONOHYDRATE) 5MG

Администрация маршрут:

INTRAVENOUS

Штук в упаковке:

100ML

Тип рецепта:

Prescription

Терапевтические области:

BONE RESORPTION INHIBITORS

Обзор продуктов:

Active ingredient group (AIG) number: 0141761003; AHFS:

Статус Авторизация:

CANCELLED PRE MARKET

Дата Авторизация:

2020-04-08

Характеристики продукта

_ _
_ACT ZOLEDRONIC ACID Product Monograph _
_Page 1 of 64_
PRODUCT MONOGRAPH
PR
ACT_ _ZOLEDRONIC ACID
(Zoledronic Acid Injection)
Sterile Solution for Intravenous Infusion
5 mg /100 mL zoledronic acid (as zoledronic acid monohydrate)
Bone Metabolism Regulator
Actavis Pharma Company
6733 Mississauga Road, Suite 400
Mississauga, Ontario
L5N 6J5
Date of Revision:
June 1, 2017
Control No.: 205792
_ _
_ACT ZOLEDRONIC ACID Product Monograph _
_Page 2 of 64_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
..................................................................................................
4
WARNINGS AND PRECAUTIONS
.................................................................................
4
ADVERSE REACTIONS
.................................................................................................
11
DRUG INTERACTIONS
.................................................................................................
25
DOSAGE AND ADMINISTRATION
.............................................................................
27
OVERDOSAGE
...............................................................................................................
29
ACTION AND CLINICAL PHARMACOLOGY
........................................................... 29
STORAGE AND STABILITY
.........................................................................................
32
SPECIAL HANDLING INSTRUCTIONS
......................................................................
32
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................ 33
PART II: SCIENTIFIC INFORMATION
..............................................................................
34
PHARMACEUTICAL INFORMATION
....................